IPHYF News and Press, Innate Pharma - Class A

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (" Innate " or the " Company "), announced today that Yannis Morel, Chief Operating Officer, will present at the AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients. Yannis Morel will presen...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the filing of its 2025 Universal Registration Document ( Document d’enregistrement universel ) for the year ending December 31, ...

2026-03-26 16:45:56 ET Innate Pharma S.A. (IPHA) Q4 2025 Earnings Call March 26, 2026 9:00 AM EDT Company Participants Stephanie Cornen - Vice President of Investor Relations, Communication & Commercial Strategy Jonathan Dickinson - CEO & Director Sonia Qua...

2026-03-26 03:53:44 ET More on Innate Pharma Seeking Alpha’s Quant Rating on Innate Pharma Historical earnings data for Innate Pharma Financial information for Innate Pharma Read the full article on Seeking Alpha For further details see: In...

Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma partnering and royalty structures IPH4502 (Nectin-4 ADC) shows prelimin...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announces that the Company will hold a conference call on Thursday, March 26, 2026 at 2 p.m. CET / 9 a.m. EDT, following the release of its financia...

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate...

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...